Caris Life Sciences, Inc. CAI

CAI Company Overview

Caris Life Sciences, Inc. is a privately held precision medicine and biotechnology company focused on molecular science, oncology diagnostics, and artificial intelligence-driven biomarker discovery. The company develops molecular profiling technologies designed to help physicians personalize cancer treatment decisions and support biopharmaceutical research. Caris operates primarily within the precision oncology, molecular diagnostics, and life sciences data analytics industries. Its core offerings include comprehensive genomic profiling, transcriptomic analysis, proteomic testing, and large-scale clinico-genomic data solutions used by healthcare providers, academic institutions, and pharmaceutical companies.

The company’s principal revenue drivers include its molecular testing services, pharmaceutical research collaborations, and data licensing activities tied to its oncology-focused database and analytics platforms. Caris has positioned itself as an integrated precision medicine platform by combining tissue-based molecular profiling with artificial intelligence and large-scale real-world clinical data. Founded in 2008 by David D. Halbert, the company initially focused on pathology and cancer profiling services before expanding into next-generation sequencing, machine learning applications, and biopharma partnerships aimed at advancing targeted therapeutics and companion diagnostics.